rifampin and 5-(4-phenylbutoxy)psoralen

rifampin has been researched along with 5-(4-phenylbutoxy)psoralen* in 1 studies

Other Studies

1 other study(ies) available for rifampin and 5-(4-phenylbutoxy)psoralen

ArticleYear
Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling.
    Developmental cell, 2018, 10-08, Volume: 47, Issue:1

    There is growing interest in pharmacological interventions directly targeting the aging process. Pharmacological interventions against aging should be efficacious when started in adults and, ideally, repurpose existing drugs. We show that dramatic lifespan extension can be achieved by targeting multiple, evolutionarily conserved aging pathways and mechanisms using drug combinations. Using this approach in C. elegans, we were able to slow aging and significantly extend healthy lifespan. To identify the mechanism of these drug synergies, we applied transcriptomics and lipidomics analysis. We found that drug interactions involved the TGF-β pathway and recruited genes related with IGF signaling. daf-2, daf-7, and sbp-1 interact upstream of changes in lipid metabolism, resulting in increased monounsaturated fatty acid content and this is required for healthy lifespan extension. These data suggest that combinations of drugs targeting distinct subsets of the aging gene regulatory network can be leveraged to cause synergistic lifespan benefits.

    Topics: Aging; Allantoin; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Drosophila melanogaster; Drug Synergism; Ficusin; Gene Expression Regulation; Gene Regulatory Networks; Insulin-Like Growth Factor I; Lipid Metabolism; Lipids; Longevity; Metformin; Rifampin; Signal Transduction; Sirolimus; Sterol Regulatory Element Binding Protein 1; Transcriptome; Transforming Growth Factor beta

2018